Atrasentan lowers the risk for a composite of kidney failure, doubling of serum creatinine, or kidney death consistently across subgroups of urinary albumin-creatinine ratio and estimated glomerular filtration rate.
Chronic kidney disease increases the risk of cardiovascular events associated with type 2 diabetes. A clinical trial sought to discover if finerenone would help patients with both of these conditions.
